Baclofen Deal Offers Amneal Biosimilars Advantage
Firm Accelerates Biosimilars Schedule, With Three Launches Now Planned For This Year
• By David Wallace
Three biosimilar launches are planned this year for Amneal • Source: Emilija Randjelovic / Alamy Stock Vector 
